# Healthcare AI Needs a Disagreement Path

<!-- EVIDENCE_GRADE_WARN: This article is limited to source-bounded governance, health IT, decision-support, safety-management, responsible-adoption, and bounded device-context material. The source basis does not include local dispute logs, override rates, committee charters, audit logs, legal analysis, measured outcomes, or named implementation proof. -->

An AI-enabled output should never become the final word in a healthcare workflow by default. It may be wrong, incomplete, hard to interpret, poorly matched to the setting, or inconsistent with a user's professional judgment.

If a workflow explains how to use an output but not how to question it, document a concern, choose an alternative action, escalate an unresolved issue, or trigger review, then the organization may have automation without a practical way to challenge it.

## Why a Visible Challenge Route Matters

A disagreement path matters because it turns concern into action instead of leaving it informal. Without a visible route, users may quietly work around an output, ignore it without documentation, or give it more authority than it deserves.

That is a governance problem before it is anything else. The issue is not whether disagreement is always right or always wrong. The issue is whether the workflow makes disagreement actionable when a user has a reason to question the output.

The route also needs to connect to real workflow use. A model name, vendor label, or dashboard field is not enough if the user still cannot tell what to do next when the output does not fit the case at hand.

## What Makes a Disagreement Path Operationally Useful

A useful disagreement path is visible at the point of use and tied to action. It helps a user move from concern to documentation, an alternative action, escalation, or review when those routes exist.

Useful fields can include:

- intended users
- output use
- challenge route
- alternate action or non-AI path
- documentation location
- escalation contact
- review trigger
- monitoring responsibility
- owner group
- unresolved evidence gaps

Not every workflow will need every field. The point is not completeness for its own sake. The point is to make it easier to route a concern instead of hiding it behind an informal workaround.

A challenge route without an alternative action, escalation contact, or review trigger can collapse into a passive label. If users can see where to click but not what happens next, the route may exist on paper without helping the workflow in practice.

## Alternate Actions, Escalation, and Review Triggers

<!-- EVIDENCE_GRADE_WARN: The examples below are governance-routing categories, not clinical instructions, legal determinations, or proof that a named organization has implemented a working challenge pathway. -->

When an output does not fit the situation, the disagreement path should show what a user can do next. That next step depends on local context, intended users, output use, and the downstream decision influenced by the output.

Possible alternate actions can include:

- document disagreement
- choose a non-AI path
- seek human review
- add missing context
- escalate to an owner group
- request workflow review
- flag a monitoring concern
- pause reliance on the output for a narrow use
- reopen governance review

These are governance-routing categories, not universal clinical instructions. The source basis supports the idea that the route should be visible enough for concerns to be documented, reviewed, and escalated when appropriate.

Escalation also needs a destination. If unresolved concerns do not reach a person or group that can clarify the use boundary, request evidence, coordinate fallback, or route governance review, the disagreement path remains weak.

Review triggers can help show when a concern has moved beyond a one-off objection. Examples include repeated disagreement, missing context, a changed setting, a disputed use boundary, common workarounds, unclear ownership, unreviewed monitoring signals, or an evidence gap that reaches a decision point.

These triggers do not prove harm, noncompliance, or model failure. They show why a concern may warrant review.

## Unknown, Unusable, and Disputed Routes Should Stay Visible

Some routes are unknown. Users may not know where to record a concern, who sees it, or who can respond. That uncertainty should remain visible as an unresolved routing problem rather than being treated as resolved.

Some routes exist but are unusable. They may be too slow, disconnected from workflow use, unclear about who responds, or unavailable to the people expected to use them. An organization cannot assume contestability is real if the challenge route exists only on paper.

Some routes are disputed. Different groups may control different parts of the workflow, or the output may influence decisions outside the original use boundary. In those cases, the disagreement record should preserve the dispute and route it to a decision-maker rather than hiding it behind a generic escalation label.

Keeping unknown, unusable, and disputed routes visible can help surface missing context, unclear ownership, unresolved evidence gaps, and monitoring questions that still need review.

## Evidence Limits

The source basis supports a cautious governance argument about contestability, documentation, escalation, monitoring, and responsible adoption. It does not prove that any named organization has a functioning disagreement route.

The available governance sources do not provide local dispute logs, override rates, committee charters, audit logs, legal analysis, measured outcomes, or named implementation proof. They also do not support clinical instructions about when a specific output should be accepted, overridden, or escalated in care.

That is why a disagreement path should be framed as a workflow and governance discipline. It can make concerns easier to route. It does not prove safety, compliance, effectiveness, fairness, trust, resilience, maturity, or outcome improvement.

## Selected Source Basis

- NIST AI RMF
- ONC SAFER
- ONC decision-support intervention material
- WHO
- AMA
- Joint Commission/CHAI
- bounded FDA AI/ML device context
